More genes from key pathways in breast cancer such as MAPK and PI3K-AKT (i.e., IGF1, NR4A1 and NGFR) or mTOR (BTG2; ref. 15) were upregulated in the NeoAI study (Supplementary Table S3). This evidence concerns the gene BTG2 and breast carcinoma.